Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) announced a major step towards achieving its net-zero carbon emissions goal by 2050. The company signed a 20-year virtual power purchasing agreement with EDF Renewables to supply 545,000 MWh of renewable electricity annually from a new 200 MW solar project in Texas. By 2026, Thermo Fisher aims to power all U.S. operations entirely with renewable electricity. This initiative supports an increased target to cut Scope 1 and 2 greenhouse gas emissions by 50% from 2018 levels by 2030. The Millers Branch Solar project is set to be operational by December 2025, marking a significant shift toward sustainable practices.
Thermo Fisher Scientific Inc. (TMO) reported its Q4 and full-year 2022 results, showing a 7% increase in quarterly revenue to $11.45 billion and a 15% increase in annual revenue to $44.92 billion. The fourth quarter GAAP EPS was $4.01, down from $4.17 in 2021, while adjusted EPS was $5.40, compared to $6.54 previously. Notable achievements included the launch of innovative products and expansions in global capabilities. The company initiated 2023 guidance, expecting $45.3 billion in revenue and $23.70 in adjusted EPS.
Thermo Fisher Scientific Inc. (NYSE: TMO) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. (EST). CEO Marc N. Casper will lead the presentation, showcasing the company's commitment to advancing science globally. Thermo Fisher, with an annual revenue of approximately $40 billion, aims to make the world healthier, cleaner, and safer.
Investors can access the presentation via the Investors section of their website.
Thermo Fisher Scientific Inc. (NYSE: TMO) is set to release its financial results for Q4 and full year 2022 on February 1, 2023, before market opening. The company will also host a conference call at 8:30 a.m. EST to discuss its financial performance and future expectations. Thermo Fisher, with annual revenue around $40 billion, emphasizes its commitment to supporting life sciences and diagnostics. Interested parties can access the call and follow the details on the company’s website.
Thermo Fisher Scientific has completed its acquisition of The Binding Site Group for £2.3 billion ($2.8 billion). This acquisition expands Thermo Fisher's Specialty Diagnostics segment, enhancing its capabilities in oncology testing for multiple myeloma. The Binding Site's offerings are crucial for early diagnosis and monitoring of blood cancers, significantly improving patient outcomes. The transaction is expected to boost adjusted earnings per share by $0.07 in 2023. Thermo Fisher continues to lead in serving science with a projected annual revenue of around $40 billion.
Summary not available.
Thermo Fisher Scientific has announced the pricing of a €1.25 billion offering of euro-denominated senior notes. The offering includes €500 million of 3.200% senior notes due 2026 and €750 million of 3.650% senior notes due 2034. The expected closing date is on or about November 21, 2022. Proceeds from this offering will fund general corporate purposes, including acquisitions and debt refinancing. The company operates under an effective registration statement with the SEC, ensuring compliance and transparency for investors.
Thermo Fisher Scientific, trading under TMO, has announced the pricing of a $1.2 billion bond offering, which includes $600 million in senior notes due 2027 with a 4.800% interest rate and $600 million in senior notes due 2032 with a 4.950% interest rate. The offering is set to close by November 21, 2022, subject to standard conditions. Proceeds will support various corporate purposes, including debt repayment and acquisitions. The offering is managed by BofA Securities, Citigroup, and Deutsche Bank.
Thermo Fisher Scientific (NYSE: TMO) has authorized a substantial share repurchase program, amounting to $4 billion. This initiative allows for the repurchase of shares in the open market or through negotiated transactions, with no expiration date set for the authorization. This strategic move aims to enhance shareholder value and reflects the company's confidence in its strong financial position, supported by an annual revenue of approximately $40 billion.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders on record as of December 15, 2022. The company reported annual revenue of approximately $40 billion, emphasizing its commitment to supporting customers in life sciences research, diagnostics, and therapeutic development. Thermo Fisher continues to lead the industry with innovative technologies and services.